We look forward to your original submissions to this meeting. Abstracts are not eligible for submission to PFD Week if:
• It was presented at a prior AUGS meeting.
• It has been or will be published as an abstract or as a full paper in a scientific, medical, or professional publication prior to PFD Week 2024.
• It was presented at another ob-gyn or urology meeting inside the United States.
Abstracts presented at a professional conference outside of the U.S. are eligible for submission.
Abstracts that have been presented at non-ob-gyn or urology meetings will be accepted for oral and poster presentations. The author must list where and when the research was presented at the time of submission.
Abstracts found to have been previously presented in violation of the above guidelines will be removed. Questions about this can be directed to education@augs.org.
The abstract must not have been published as an abstract or as a full paper in any scientific, medical, or professional publication prior to presentation at PFD Week 2024.
IRB REVIEW
Institutional Review Boards (IRB) are charged with protecting the rights and welfare of people involved in research. IRB approval or waiver is required for submission of all abstracts, including videos. You will be required during online submission to document whether your study has been IRB-reviewed. You will be asked to enter the unique IRB identifier number in the space provided on the web form. If approval is waived by an IRB, AUGS must receive a copy of the waiver letter by the submission deadline.
FINANCIAL RELATIONSHIP DISCLOSURE
AUGS is accredited by the ACCME. To participate as a person who will be able to control the educational content of this accredited CE activity, all presenters, faculty, authors, AND all co-authors are asked to disclose all financial relationships with any ineligible companies over the past 24 months. We define ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; presenters must disclose all financial relationships, regardless of the amount, with ineligible companies. We ask presenters to disclose regardless of whether they view the financial relationships as relevant to the education. For more information on the Standards for Integrity and Independence in Accredited Continuing Education, please visit www.accme.org/standards.
These relationships will not disqualify an abstract but may affect the type of presentation and/or scheduling.
Co-authors will be required to submit their own disclosures. It is not the responsibility of the submitting author to complete their disclosures. Incomplete disclosures by co-authors will result in an incomplete abstract submission.
CHARACTER LIMIT
• Title character limit: No more than 80 characters.
• Body character limit: There is a combined limit of 450 words which includes Objective, Methods, Results, and Conclusions. You will be advised of your word count usage throughout the submission process as you save and move to the next step. This count does not include title, authors or affiliations.
• Figures and Tables Limit: You may add a total of two figures and/or tables. Tables must be submitted as a Word document. DO NOT include legends with your figure/table upload. All legends should appear in the body of the abstract and be clearly labeled. Figures and tables cannot be in color. Figures and tables will appear at the end of your abstract, both on the proof and for publication.
All abstracts should be submitted in English. Omit ALL person, group, and institutional names and geographical references in the body of the abstract. Abstracts that do not adhere to this and unblind themselves within the body of the abstract are subject to downgrading.
VIDEO ABSTRACT
Videos that address topics such as surgical tips, anatomy, or educational topics are encouraged. Please ensure that your videos protect patient anonymity and integrity. The time limit for a video is 8 minutes. Video abstract submission should contain a brief description of the Objectives, Methods, and Clinical Relevance of the video submission with a maximum word count of 450 words (same as abstract).
The below criteria must be met for acceptance of video presentation.
• Maximum duration: 8 minutes
• File cannot be above 2.0 GB
• Videos must have English captions or narration
• Avoid any background music that is too loud or distracting
• Please ensure that your videos protect patient anonymity and integrity.
• Acceptable file formats are .mp3, .avi, .mov, .mpg, .mp4 and .m4a
Please remove all product logos/names from your video. If a video is submitted with the product name/logo included, the video will be disqualified from consideration.
LATE-BREAKING SCIENCE
Late-breaking science submissions are intended to allow for the timely presentation of high-impact trials to PFD Week 2024 attendees. It is expected that these abstract submissions are from studies for which no preliminary data were available at the time of the abstract submission deadline. Submissions that do not meet these criteria will be declined. Late-breaking submissions, upon acceptance, will be invited to be presented at the podium but will not be published in the program book or Urogynecology.
Priority will be given (in the following order) to:
• Results of phase III clinical trials
• Results of phase II clinical trials
• Extraordinary findings from a basic science investigation
• Interim analyses of phase III trials that describe important secondary endpoints
• Prospective multi-institution clinical trials
Late-breaking submissions, upon acceptance, will be invited to be presented at the podium but will not be published in the program book or Urogynecology.
We reserve the option not to accept any late-breaking science abstracts if the above criteria are not satisfied by any submissions.
TITLE
• Please make sure you double-check your title, as it will be published as submitted.
• Use mixed case for title – do not use all caps or all lowercase. Do not put your title in quotation marks.
• Titles are limited to 2 lines and no more than 80 characters.
• Do not include the trial group name in the title of the abstract.
AUTHORS
• Please consult with your co-authors on how they would like their names to appear. Please enter all authors in the order they should appear in the heading of the abstract. The submitting author is automatically considered the Presenter on a submission.
• All authors and co-authors must disclose all financial relationship(s) with ineligible companies over the last 24 months at the time of submission.
Responsibilities of the Presenting Author
The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract.
The presenting author is responsible for the following:
• Ensuring that all authors have read the abstract and agreed to be co-authors.
• Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by AUGS.
PRESENTER SUBSTITUTIONS
The primary author submitting the abstract must be the presenter and be involved in the research. All oral presentations are expected to be presented onsite in Washington, DC. Presenter substitutions will only be allowed for significant changes in life circumstances or acute illness and require request and approval. Switching to a virtual presentation will not be possible.
ABSTRACT BODY
Omit all names and geographical references in the body of the abstract. Organize content in sections as follows:
• Objective: describes the research objective
• Methods: describes the research methodology used
• Results: summarizes evaluation, including outcome data
• Conclusions: states the conclusions drawn from the results
PRODUCT NAME USAGE
• For purposes of blind scoring, institutional names must be omitted whenever possible in the title and body of the abstract.
• Avoid the use of commercially branded names. Use scientific or generic names when referring to products
• If a specific device is only identifiable by its trade name, then this should appear in brackets after a generic description of the device.
• Should it be necessary to use a trade name, then the trade names of all similar products or those within a class must be used.
PROOFREAD YOUR ABSTRACT
• Carefully proofread your abstract. Make sure all special characters and formatting are displaying properly in your proof.
• You may return to the online submission site to revise your abstract until April 11, 2024, at 8:00 PM, ET.
• When making edits to a submitted abstract, you must save and re-submit by clicking the "continue" button.
• After this date/time, the submission site will close, and no additional changes/edits can be made.
• If you have not completed all required sections, including financial disclosures for all co-authors, you will not be able to complete your submission.
ABSTRACT REVIEW
• After the submission site closes, completed abstracts will be peer-reviewed.
• All abstracts will be blinded for review without knowledge of the author/s, institution/s, or disclosure information.
• Accepted abstracts will be selected as oral, short oral, scientific salon, or poster.
• Final assignments will be decided by the PFD Week Review Committee.
ABSTRACT ACCEPTANCE/REJECTION NOTIFICATIONS
• You will be notified electronically of the acceptance of your abstract during the week of June 12, 2023.
• This notification will include the date and time of your session as well as the type of presentation.
• Only the presenting author will be notified. It is the responsibility of the presenting author to notify all co-authors.
FULL PAPERS
Abstracts selected for oral presentation require the completion of a full scientific paper. This manuscript will be submitted to the program committee for use of determining abstract awards and session moderation. It will not be automatically submitted to a journal for publication but is highly encouraged.
WITHDRAWALS
• Presenting authors may withdraw an abstract submission at any time. To withdraw a submission, log into the abstract submission site, click on the title of the abstract and update the status to “withdraw”.
• In order for an accepted abstract to be withdrawn and not appear in publication, notification must be received by July 12, 2024.
• After July 12, 2024, withdrawals are still accepted but abstracts may still appear in annual meeting materials.